Olga V. Roshchina

Olga V. Roshchina

Auto-generated profile, based on publicly available information

Olga V. Roshchina

Mental Health Research Institute, Tomsk National Research Medical Center of Russian Academy Sciences

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in The World Journal of Biological Psychiatry
Verified
Journal Article
Open access
IMIrina Mednova
Irina Mednova
LLLyudmila Levchuk
Lyudmila Levchuk
ABAnastasiia Sergeevna Boiko
Anastasiia Sergeevna Boiko
OROlga V. Roschina
Olga V. Roschina
GSGerman Simutkin
German Simutkin
SISvetlana Ivanova
Svetlana Ivanova
Because alcohol use disorder (AUD) is often accompanied by mood disorder (MD) and both alcoholism and depression result in activation of the immune system, this study compares serum cytokine levels...

14 January 2020 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
ORO. V. Roshchina
O. V. Roshchina
ARA. I. Rozin
A. I. Rozin
ESEvgeny Schastnyy
Evgeny Schastnyy
NBNikolay A. Bokhan
Nikolay A. Bokhan
The aim was to study the clinical-psychopathological, clinical-follow-up, clinical-dynamic features of mood disorders (MD) and alcohol use disorder (AUD) with their comorbidity combinations.Materials and methods. The study included 88 people with AUD and MD: 33 women (37.5%) and 55 (62.5%) men. The first group was 31 patients (35,0%) with AUD without comorbid affective symptoms, the second was 29 patients (33.0%) with MD without alcohol dependence, and the third was 28 patients (32.0%) with comorbid AUD and MD. There were no statistically significant differences between the groups by age and sex composition, by the level of statistical significance of differences (p = 0.115 – by sex, ð = 0.248 – by age). The study used clinical, psychopathological, clinical and follow-up, clinical, dynamic and statistical methods. Statistical processing was performed using Pearson’s χ2, Mann – Whitney U-test for comparing independent samples and Spearman’s correlation analysis (r).Results. Patients of the second and third groups were diagnosed with dysthymia more rarely in statistically significant values by the level of statistical significance of differences (10.4% and 32.1% respectively, p = 0.023) and this testifies to MD taking chronic course in patients with AUD. The average duration of bout of heavy-drinking in the first group was longer than in the third group – 7 (4; 17) and 5,5 (3.5; 9.5) days accordingly (p = 0.043). Duration of the disease in the first and third groups was 10 (6; 18.5) and 14 (10; 19.75) years, respectively (p = 0.036). It confirms the negative impact of comorbidity on the clinicaldynamic features in the case of co-existing of AUD and MD.Conclusion. The coexistence of alcohol dependence and affective pathology enhances the suicidal risk of certain diseases. A tendency to the early appearance of symptoms of AUD and their rapid dynamics, a shorter duration of light intervals of MD and AUC, a relatively low tolerance to alcohol and pronounced depressogenic effect of alcohol in the case of comorbidity were found.

3 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OROlga V. Roschina
Olga V. Roschina
LLLyudmila Levchuk
Lyudmila Levchuk
ABAnastasiia Sergeevna Boiko
Anastasiia Sergeevna Boiko
EMEkaterina Mikhalitskaya
Ekaterina Mikhalitskaya
Elena EpimakhovaElena Epimakhova
Elena Epimakhova
SISvetlana Ivanova
Svetlana Ivanova
Background: The neuropeptides β-endorphin and oxytocin are released into the bloodstream as hormones from the pituitary gland but also have an important function as neuroregulators in the forebrain. The blood levels of both polypeptides have been shown to reflect depressive symptoms. β-Endorphin, in particular, is also involved in abstinence from alcohol. Methods: The serum levels of β-endorphin and oxytocin were measured during the early withdrawal phase in patients with alcohol use disorder (AUD) with (N = 35) or without (N = 45) depressive comorbidity and compared with those in healthy volunteers (N = 23). In addition to comparing the groups, the study examined whether serum levels correlated with various psychometric measures of dependence, depression and aggression, as well as with clinical characteristics of dependence. Results: Both serum levels of beta-endorphin and oxytocin were significantly lower in patients than those in healthy controls (p = 0.011 for β-endorphin and p = 0.005 for oxytocin, Kruskal–Wallis test). In patients with depressive comorbidity, the significance was greatest (p = 0.005 for β-endorphin and p = 0.004 for oxytocin, U-test). There was no correlation with clinical or psychometric parameters (p > 0.05, Spearman test), but beta-endorphin levels did correlate significantly with physical aggression (p = 0.026, Spearman test). Conclusions: Serum levels of β-endorphin and oxytocin are lower in patients with AUD, particularly in those with depressive comorbidity. β-Endorphin levels correlated with physical aggression according to the Buss–Durkee (BDHI) estimates.

21 September 2023 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
LLLyudmila Levchuk
Lyudmila Levchuk
OROlga V. Roschina
Olga V. Roschina
EMEkaterina Mikhalitskaya
Ekaterina Mikhalitskaya
Elena EpimakhovaElena Epimakhova
Elena Epimakhova
GSGerman Simutkin
German Simutkin
SISvetlana Ivanova
Svetlana Ivanova
Nowadays, nervous tissue damage proteins in serum are considered promising drug targets and biomarkers of Mood Disorders. In a cross-sectional naturalistic study, the S100B, MBP and GFAP levels in the blood serum were compared between two diagnostic groups (patients with Depressive Episode (DE, n = 28) and patients with Recurrent Depressive Disorder (RDD, n = 21)), and healthy controls (n = 25). The diagnostic value of serum markers was assessed by ROC analysis. In the DE group, we did not find changed levels of S100B, MBP and GFAP compared with controls. In the RDD group, we found decreased S100B level (p = 0.011) and increased MBP level (p = 0.015) in comparison to those in healthy controls. Provided ROC analysis indicates that MBP contributes to the development of a DE (AUC = 0.676; 95%Cl 0.525–0.826; p = 0.028), and S100B and MBP have a significant effect on the development of RDD (AUC = 0.732; 95%Cl 0.560–0.903; p = 0.013 and AUC = 0.712; 95%Cl 0.557–0.867; p = 0.015, correspondingly). The study of serum markers of nervous tissue damage in patients with a current DE indicates signs of disintegration of structural and functional relationships, dysfunction of gliotransmission, and impaired secretion of neurospecific proteins. Modified functions of astrocytes and oligodendrocytes are implicated in the pathophysiology of RDD.

7 January 2021 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
SGStanislav Galkin
Stanislav Galkin
Anastasia PeshkovskayaAnastasia Peshkovskaya
Anastasia Peshkovskaya
ORO. V. Roshchina
O. V. Roshchina
НКН. И. Кисель
Н. И. Кисель
SISvetlana Ivanova
Svetlana Ivanova
NBNikolay A. Bokhan
Nikolay A. Bokhan
Особенности мозговой активности при алкогольной зависимости в задаче на ингибиторный контроль

6 February 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
ACAlexander A. Chernonosov
Alexander A. Chernonosov
IMIrina Mednova
Irina Mednova
LLLyudmila Levchuk
Lyudmila Levchuk
EMEkaterina O. Mazurenko
Ekaterina O. Mazurenko
OROlga V. Roschina
Olga V. Roschina
SISvetlana Ivanova
Svetlana Ivanova
Depressive disorder is a multifactorial disease that is based on dysfunctions in mental and biological processes. The search for biomarkers can improve its diagnosis, personalize therapy, and lead to a deep understanding of the biochemical processes underlying depression. The purpose of this work was a metabolomic analysis of blood serum to classify patients with depressive disorders and healthy individuals using Compound Discoverer software. Using high-resolution mass spectrometry, blood plasma samples from 60 people were analyzed, of which 30 were included in a comparison group (healthy donors), and 30 were patients with a depressive episode (F32.11) and recurrent depressive disorder (F33.11). Differences between patient and control groups were identified using the built-in utilities in Compound Discoverer software. Compounds were identified by their accurate mass and fragment patterns using the mzCloud database and tentatively identified by their exact mass using the ChemSpider search engine and the KEGG, ChEBI, FDA UNII-NLM, Human Metabolome and LipidMAPS databases. We identified 18 metabolites that could divide patients with depressive disorders from healthy donors. Of these, only two compounds were tentatively identified using the mzCloud database (betaine and piperine) based on their fragmentation spectra. For three compounds ((4S,5S,8S,10R)-4,5,8-trihydroxy-10-methyl-3,4,5,8,9,10-hexahydro-2H-oxecin-2-one, (2E,4E)-N-(2-hydroxy-2-methylpropyl)-2,4-tetradecadienamide and 17α-methyl-androstan-3-hydroxyimine-17β-ol), matches were found in the mzCloud database but with low score, which could not serve as reliable evidence of their structure. Another 13 compounds were identified by their exact mass in the ChemSpider database, 9 (g-butyrobetaine, 6-diazonio-5-oxo-L-norleucine, 11-aminoundecanoic acid, methyl N-acetyl-2-diazonionorleucinate, glycyl-glycyl-argininal, dilaurylmethylamine, 12-ketodeoxycholic acid, dicetylamine, 1-linoleoyl-2-hydroxy-sn-glycero-3-PC) had only molecular formulas proposed, and 4 were unidentified. Thus, the use of Compound Discoverer software alone was not sufficient to identify all revealed metabolites. Nevertheless, the combination of the found metabolites made it possible to divide patients with depressive disorders from healthy donors.